Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Cambia visualizzazione
| Taglio della confezione | SKU | Disponibilità | Prezzo |
|---|---|---|---|
| 10 mg | Per informazioni sulla disponibilità, contatta il Servizio Clienti. | 96,40 € | |
| 50 mg | Per informazioni sulla disponibilità, contatta il Servizio Clienti. | 381,00 € 323,85 € |
Informazioni su questo articolo
Formula empirica (notazione di Hill):
C5H14N2S · 2HCl
Numero CAS:
Peso molecolare:
207.16
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
96,40 €
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiNome del prodotto
WR-1065, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to off-white
solubility
H2O: ≥20 mg/mL
storage temp.
−20°C
SMILES string
Cl.Cl.NCCCNCCS
InChI
1S/C5H14N2S.2ClH/c6-2-1-3-7-4-5-8;;/h7-8H,1-6H2;2*1H
InChI key
XDRLRDHLCIFZIW-UHFFFAOYSA-N
Biochem/physiol Actions
WR-1065 is a cytoprotective cell-permeable ROS scavenge and an active metabolite of Amifostine.
WR-1065 is cytoprotective cell-permeable reactive oxygen species scavenger and p53 activator and re-activator. Recently shown to have antiretroviral activity and an active metabolite of Amifostine which selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy.
WR-1065 is the active metabolite of the prodrug amifostine, generated by alkaline phosphatase. It is found to accumulate in many epithelial tissues. WR-1065 protects cellular membranes and DNA from free radical induced damage.
1 of 1
Questo articolo | |||
|---|---|---|---|
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥97% (HPLC) |
| form powder | form powder | form powder | form powder |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. −20°C | storage temp. room temp | storage temp. −20°C | storage temp. 2-8°C |
| storage condition desiccated | storage condition desiccated | storage condition desiccated | storage condition desiccated |
| solubility H2O: ≥20 mg/mL | solubility H2O: >15 mg/mL | solubility H2O: 20 mg/mL, clear | solubility H2O: 20 mg/mL, clear |
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Dam. 1
Classe di stoccaggio
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Trevor McKibbin et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(3), 1049-1057 (2010-01-28)
We evaluated the pharmacokinetics of amifostine and WR1065 in pediatric patients with newly diagnosed medulloblastoma to assess the influence of patient covariates, including demographics, clinical characteristics, and genetic polymorphisms, on amifostine and WR1065 pharmacokinetic parameters. We assessed the pharmacokinetics of
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer
Jellema AP, et al.
Cancer, 107(3), 544-553 (2006)
Caroline Prouillac et al.
Free radical biology & medicine, 46(8), 1139-1148 (2009-05-15)
Thiol and aminothiol compounds are among the most efficient chemical radioprotectors. To increase their efficiency, we synthesized two new classes of thiol and aminothiol compounds derived from benzothiazole (T1, T2, AM1, AM2) and thiadiazole (T3, T4, AM3) structures. We examined
Numero articolo commerciale globale
| SKU | GTIN |
|---|---|
| W2020-50MG | 04061837488993 |
| W2020-10MG | 04061832725864 |





